O Citi foi o assessor exclusivo da ROCHE na compra da Telavant, controlada pela Roivant Sciences e pela Pfizer, for $7,25 bilhões.
On October 23rd, 2023, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc, for $7.25 billion. The agreement includes the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a promising new therapy for people suffering from inflammatory bowel disease. Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million.
Telavant’s RVT-3101 is Phase-3 ready potential first-in-class agent that targets both inflammatory and fibrotic pathways by inhibiting TL1A, a protein in the immune system that is associated with autoimmune diseases. RVT-3101 has shown positive results in a Phase 2b study in patients with moderate to severe ulcerative colitis. A Phase 2 study evaluating RVT-3101 in Crohn’s disease is ongoing.
Pfizer holds a 25% equity interest in Telavant and retains commercial rights outside of the US and Japan. Roche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1.
The transaction closing is currently expected in Q4 2023 or Q1 2024 and is subject to customary closing conditions, including regulatory approvals.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.
Citi acted as exclusive financial advisor to Roche.
Fonte: Citi